tbuckley/cabot-search huggingface dataset:
The SF3B1 K700E Mutation Induces R-Loop Accumulation and Associated DNA Damage
Authors: Shalini Singh, Doaa Ahmed, Hamid Dolatshad, Dharamveer Tatwavedi, Ulrike Schulze, Andrea Sanchi, Sarah Ryley, Ashish Dhir, Lee Carpenter, Suzanne M. Watt, Amal M. Abdel-Aal, Sohair K. Sayed, Somia A. Mohamed, Anna Schuh, Nicholas J. Proudfoot, Andriana G. Kotini, Eirini P. Papapetrou, Daniel Wiseman, Andrea Pellagatti, Jacqueline Boultwood
Journal: Blood (2019)
Evolving Treatment Trends in Relapsed/Refractory Multiple Myeloma (RRMM) in Europe from 2016 to 2018: Analysis of a Multi-National Survey
Authors: Maximilian Merz, Isabelle Vande Broek, Manuel Pérez, Brigitte Kolb, Argiris Symeonidis, Emmanouil Nikolousis, Athanasios Zomas, Francisco Gonzalez, Lenka Kellermann, Hartmut Goldschmidt
Journal: Blood (2019)
Diagnostic 2-Gene Classifier in Early-Stage Mycosis Fungoides: A Retrospective Multicenter Study
Authors: Pia Rude Nielsen, Jens Ole Eriksen, Lise M. Lindahl, Ulrike Wehkamp, Gitte Rinds Andersen, Michael Bzorek, Kirsten Grønbæk, Niels Odum, Thomas Litman, Lise Mette Rahbek Gjerdrum
Journal: Blood (2019)
Prognostic Value of Minimal Residual Disease Measured By Flow Cytometry in Two Cohorts of Infants with Acute Lymphoblastic Leukemia Treated with MLL-Baby and Interfant Protocols in Large Multicenter Networks
Authors: Alexander Popov, Barbara Buldini, Paola De Lorenzo, Silvia Disaro, Tatiana Verzhbitskaya, Liudmila Movchan, Emanuela Giarin, Egor Shorikov, Annamaria Di Meglio, Grigory Tsaur, Franco Locatelli, Rosanna Parasole, Natalia Miakova, Elmira Boychenko, Konstantin Kondratchik, Olga Aleinikova, Alexander Karachunskiy, Alexander Roumiantsev, Andrea Biondi, Rob Pieters, Maria Grazia Valsecchi, Larisa Fechina, Giuseppe Basso
Journal: Blood (2019)
EHMT2 Inhibitor BIX-01294 Induces Endoplasmic Reticulum Stress Mediated Apoptosis and Autophagy in Diffuse Large B Cell Lymphoma Cells
Authors: Linyan Xu, Xiang Gao, Wei Sang, Dongmei Yan, Xuguang Song, Feng Zhu, Kailin Xu
Journal: Blood (2019)
Cancer of the Prostate
Authors: Rita T. Layson
Journal: JAMA (1992)

To the Editor.  —The Editorial by Oesterling 1 recommended screening all men over the age of 55 years for early prostate cancer with annual DRE and PSA levels. This recommendation violates one of the basic principles for deciding to screen for a medical condition during periodic health examinations. In order for a screening procedure to be beneficial, there must be evidence that treating the disease earlier results in decreased morbidity. In the Editorial, Oesterling admits that there is no conclusive evidence that early treatment with radical prostatectomy or radiation therapy is beneficial for all patients with early prostate cancer. Consequently, recommending mass screening for early prostate cancer at this time is, at best, premature. In light of the great variability in the natural history of untreated early prostate cancer reported by Johansson et al, 2 it seems more prudent to await proof that treating early prostate cancer does improve morbidity
Artificial antigen presenting cells for detection and desensitisation of auto-reactive T-cells associated with Type 1 Diabetes
Authors: E Abu Shah, A Artzy-Schnirman, R Chandrawati, E Altman, N Yusuf, C Wang, J Ramos, M Haus-Cohen, R Dahan, S Arif, M Dustin, M Peakman, Y Reiter, M Stevens
Journal: Biomaterials (2019)
Largest Single Center Experience Using Dual T-Cell Depletion with ATG and Ptcy for Gvhd Prophylaxis in Peripheral Blood RIC Allo-HSCT
Authors: Maria Queralt Salas, Arjun Law, Wilson Lam, Fotios V. Michelis, Dennis Dong Hwan Kim, David Loach, Zeyad Al-Shaibani, Jeffrey H. Lipton, Rajat Kumar, Jonas Mattsson, Auro Viswabandya
Journal: Blood (2019)
Clinical and Magnetic Resonance Imaging (MRI) Decision Making Rules in Differentiating Vaso-Occlusive Crises (VOCs) from Osteomyelitis in Paediatric Sickle Cell Population: Is MRI Pathognomonic?
Authors: Ahmed khalifa Al Shukaili, Ahmed Abdullah Al Kharusi, Eyad Tbaileh, Hanan Nazir, Sameer Raniga, Alaa Al Manzalawy, Mohamed Ebrahim Mohamed Ebrahim Elshinawy, Zaid Al Hinai, Laila Al Yazidi, Murtadha Al-Khabori, Yasser Wali
Journal: Blood (2019)
Ethics of Human Experimentation
Authors: A. G. Cox
Journal: BMJ (1963)

<h3>ABSTRACT</h3> The role the mammary epithelial circadian clock plays in gland development and lactation is unknown. We hypothesized that mammary epithelial clocks function to regulate mammogenesis and lactogenesis, and propose the core clock transcription factor BMAL1:CLOCK regulates genes that control mammary epithelial development and milk synthesis. Our objective was to identify transcriptional targets of BMAL1 in undifferentiated (UNDIFF) and lactogen differentiated (DIFF) mammary epithelial cells (HC11) using ChIP-seq. Ensembl gene IDs with the nearest transcriptional start site to peaks were explored as potential targets, and represented 846 protein coding genes common to UNDIFF and DIFF cells and 2773 unique to DIFF samples. Genes with overlapping peaks between samples (1343) enriched cell-cell adhesion, membrane transporters and lipid metabolism categories. To functionally verify targets, an HC11 line with <i>Bmal1</i> gene knocked out (BMAL1-KO) using CRISPR-CAS was created. BMAL1-KO cultures had lower cell densities over an eight-day growth curve, which was associated with increased (p&lt;0.05) levels of reactive oxygen species and lower expression of superoxide dismutase 3 (<i>Sod3</i>). Q-PCR analysis also found lower expression of the putative targets, prolactin receptor (<i>Prlr</i>), <i>Ppara</i>, and beta-casein (<i>Csn2</i>). Findings support our hypothesis and highlight potential importance of clock in mammary development and substrate transport.
PDTM-11. GAINING INSIGHTS INTO THE INFLAMMATORY MICROENVIRONMENT OF PEDIATRIC HIGH-GRADE GLIOMAS USING GEMMs AND PATIENT SAMPLES
Authors: James Ross, Zhihong Chen, Cameron Herting, Frank Szulzewsky, Oren Becher, Tobey MacDonald, Matthew Schniederjan, Dolores Hambardzumyan
Journal: Neuro-Oncology (2019)

Abstract Pediatric high-grade gliomas (pHGG) account for the most cancer-related deaths in children, as there are no effective therapies available. It is known tumor associated macrophages (TAM) can make up 30–40% of the total tumor cell mass in adult high-grade gliomas, promoting tumor growth and immune evasion. This raises the question of whether pHGGs possess a distinct constituency of TAMs due to their unique genetic and epigenetic landscapes. To uncover the composition and behavior of TAMs in pHGG we utilize RCAS/tva, a somatic cell-type specific gene transfer system which allows us to recapitulate all major subtypes of pHGG in newborn immunocompetent mice, including histone wild-type and histone-mutant tumors. We combine RCAS-H3.3K27M, RCAS-H3.3G34R/V, or RCAS-H3.3WT along with their driver mutations such as RCAS-shp53 and RCAS-PDGFA or RCAS-PDGFB. These tumors are induced in Nestin-positive cells, each in their respective locations found in the human population. Tumors driven by PDGFB have a significantly lower median survival compared to PDGFA-driven tumors and have increased infiltration of lymphocytes and TAMs, specifically inflammatory monocytes. In vitro bone marrow derived monocyte and microglial cultures demonstrate the BMDM population is most responsible for the production of inflammatory chemokines and angiogenic factors in the tumor microenvironment. We performed histological analyses on over 40 human patient samples to determine the role of the stromal population in TAM infiltration. Matched human samples were also utilized for pan-cancer immune profiling with NanoString to further characterize the innate and adaptive immune microenvironments. These analyses indicate DIPG/K27M tumors have a higher immune cell infiltrate compared to G34R/V and histone wildtype tumors. Further, we observe higher infiltration of T-cell populations in pHGGs compared to adult HGGs, suggesting these tumors may be amenable to immunotherapy despite being considered “immune cold.” These studies provide the critical foundation needed for the development of novel therapeutics targeting these tumors.
Non-Bcl2 Mutations Are Predominant in Patients (pts) with Venetoclax Resistant Mantle Cell Lymphoma (MCL) - Response and Clinical Outcomes in Ultra-Refractory MCL
Authors: Preetesh Jain, Shuangtao Zhao, Rashmi Kanagal-Shamanna, Lucy Navsaria, Holly Hill, Ankita Misra, Krystle Nomie, Changying Jiang, Yixin Yao, Liang Zhang, Loretta J. Nastoupil, F. B. Hagemeister, Jason R. Westin, Ranjit Nair, Raphael Eric Steiner, Onyeka Oriabure, Wendy Chen, Guilin Tang, C. Cameron Yin, Keyur Patel, Jorge Enrique Romaguera, Nathan H. Fowler, Linghua Wang, Michael L. Wang
Journal: Blood (2019)
Deciphering the Role of Locally Disordered DNA Methylation on CLL Development In Vivo
Authors: Anat Biran, Helene Kretzmer, Shanye Yin, Leah Billington, Fara Faye Regis, Arman W. Mohammad, Andreas Gnirke, Donna S Neuberg, Ruben D. Carrasco, Alexander Meissner, Catherine J. Wu
Journal: Blood (2019)
Identifying Novel Mechanisms of Resistance to Tyrosine Kinase Inhibitors in Anaplastic Large Cell Lymphoma
Authors: Elif Atabay, Qi Wang, Ambrogio Chiara, Taek-Chin Cheong, Silvia Peola, Geeta G Sharma, Luca Mologni, Carlo Gambacorti-Passerini, Claudia Voena, Roberto Chiarle
Journal: Blood (2019)
Long-Term Experience with Large Granular Lymphocytic Leukemia Evolving after Solid Organ and Hematopoietic Stem Cell Transplantation
Authors: Hassan Awada, Reda Z. Mahfouz, Jibran Durrani, Ashwin Kishtagari, Deepa Jagadeesh, Alan Lichtin, MD, Brian T. Hill, Betty K. Hamilton, Hetty E. Carraway, Navneet S. Majhail, Ronald Sobecks, Valeria Visconte, Matt Kalaycio, Mikkael A. Sekeres, Jaroslaw P. Maciejewski
Journal: Blood (2019)
B cell tolerance and antibody production to the celiac disease autoantigen transglutaminase 2
Authors: M. Fleur du Pré, Jana Blazevski, Alisa E. Dewan, Jorunn Stamnaes, Chakravarthi Kanduri, Geir Kjetil Sandve, Marie K. Johannesen, Christian B. Lindstad, Kathrin Hnida, Lars Fugger, Gerry Melino, Shuo-Wang Qiao, Ludvig M. Sollid
Journal: The Journal of Experimental Medicine (2019)

Autoantibodies to transglutaminase 2 (TG2) are hallmarks of celiac disease. To address B cell tolerance and autoantibody formation to TG2, we generated immunoglobulin knock-in (Ig KI) mice that express a prototypical celiac patient–derived anti-TG2 B cell receptor equally reactive to human and mouse TG2. We studied B cell development in the presence/absence of autoantigen by crossing the Ig KI mice to Tgm2−/− mice. Autoreactive B cells in Tgm2+/+ mice were indistinguishable from their naive counterparts in Tgm2−/− mice with no signs of clonal deletion, receptor editing, or B cell anergy. The autoreactive B cells appeared ignorant to their antigen, and they produced autoantibodies when provided T cell help. The findings lend credence to a model of celiac disease where gluten-reactive T cells provide help to autoreactive TG2-specific B cells by involvement of gluten–TG2 complexes, and they outline a general mechanism of autoimmunity with autoantibodies being produced by ignorant B cells on provision of T cell help.
Effect of Vitamin D and Omega-3 Fatty Acid Supplementation on Kidney Function in Patients With Type 2 Diabetes
Authors: Ian H. de Boer, Leila R. Zelnick, John Ruzinski, Georgina Friedenberg, Julie Duszlak, Vadim Y. Bubes, Andrew N. Hoofnagle, Ravi Thadhani, Robert J. Glynn, Julie E. Buring, Howard D. Sesso, JoAnn E. Manson
Journal: JAMA (2019)

Chronic kidney disease (CKD) is a common complication of type 2 diabetes that can lead to end-stage kidney disease and is associated with high cardiovascular risk. Few treatments are available to prevent CKD in type 2 diabetes.To test whether supplementation with vitamin D3 or omega-3 fatty acids prevents development or progression of CKD in type 2 diabetes.Randomized clinical trial with a 2 × 2 factorial design conducted among 1312 adults with type 2 diabetes recruited between November 2011 and March 2014 from all 50 US states as an ancillary study to the Vitamin D and Omega-3 Trial (VITAL), coordinated by a single center in Massachusetts. Follow-up was completed in December 2017.Participants were randomized to receive vitamin D3 (2000 IU/d) and omega-3 fatty acids (eicosapentaenoic acid and docosahexaenoic acid; 1 g/d) (n = 370), vitamin D3 and placebo (n = 333), placebo and omega-3 fatty acids (n = 289), or 2 placebos (n = 320) for 5 years.The primary outcome was change in glomerular filtration rate estimated from serum creatinine and cystatin C (eGFR) from baseline to year 5.Among 1312 participants randomized (mean age, 67.6 years; 46% women; 31% of racial or ethnic minority), 934 (71%) completed the study. Baseline mean eGFR was 85.8 (SD, 22.1) mL/min/1.73 m2. Mean change in eGFR from baseline to year 5 was -12.3 (95% CI, -13.4 to -11.2) mL/min/1.73 m2 with vitamin D3 vs -13.1 (95% CI, -14.2 to -11.9) mL/min/1.73 m2 with placebo (difference, 0.9 [95% CI, -0.7 to 2.5] mL/min/1.73 m2). Mean change in eGFR was -12.2 (95% CI, -13.3 to -11.1) mL/min/1.73 m2 with omega-3 fatty acids vs -13.1 (95% CI, -14.2 to -12.0) mL/min/1.73 m2 with placebo (difference, 0.9 [95% CI, -0.7 to 2.6] mL/min/1.73 m2). There was no significant interaction between the 2 interventions. Kidney stones occurred among 58 participants (n = 32 receiving vitamin D3 and n = 26 receiving placebo) and gastrointestinal bleeding among 45 (n = 28 receiving omega-3 fatty acids and n = 17 receiving placebo).Among adults with type 2 diabetes, supplementation with vitamin D3 or omega-3 fatty acids, compared with placebo, resulted in no significant difference in change in eGFR at 5 years. The findings do not support the use of vitamin D or omega-3 fatty acid supplementation for preserving kidney function in patients with type 2 diabetes.ClinicalTrials.gov Identifier: NCT01684722.
Capecitabine and Temozolomide versus FOLFIRI in RAS-Mutated, MGMT-Methylated Metastatic Colorectal Cancer
Authors: Filippo Pietrantonio, Riccardo Lobefaro, Maria Antista, Sara Lonardi, Alessandra Raimondi, Federica Morano, Stefania Mosconi, Lorenza Rimassa, Sabina Murgioni, Andrea Sartore-Bianchi, Gianluca Tomasello, Raffaella Longarini, Gabriella Farina, Fausto Petrelli, Stefania Gori, Giovanni Randon, Salvatore Corallo, Filippo Pagani, Vincenzo Guarini, Federica Palermo, Antonia Martinetti, Marco Macagno, Ludovic Barault, Federica Perrone, Elena Tamborini, Massimo Milione, Federica Di Nicolantonio, Massimo Di Maio, Giovanni Fucà, Maria Di Bartolomeo, Filippo de Braud
Journal: Clinical Cancer Research (2019)

To determine whether second-line therapy with capecitabine and temozolomide was superior to irinotecan, leucovorin, and fluorouracil (FOLFIRI) in patients with RAS-mutated, methyl-guanine methyltransferase (MGMT)-methylated metastatic colorectal cancer (mCRC).In this randomized, phase II trial, we enrolled patients with RAS-mutated, MGMT-methylated mCRC after failure of oxaliplatin-based regimen. Patients with centrally confirmed MGMT methylation were stratified by first-line progression-free survival (PFS) and prior bevacizumab and randomized to either capecitabine plus temozolomide (arm A, CAPTEM) or FOLFIRI (arm B). The primary endpoint was PFS analyzed on intention-to-treat basis, with 90% power and one-sided significance level of 0.05 to detect an increase of median time from 2 months in arm B to 4 months in arm A.Between November 2014 and May 2019, 86 patients were randomly assigned to arm A (n = 43) or arm B (n = 43). After a median follow-up of 30.5 months (interquartile range, 12.2-36.3), 79 disease progression or death events occurred. Superiority of arm A was not demonstrated (one-sided P = 0.223). Progression-free survival and overall survival were 3.5 (2.0-5.0) and 9.5 (8.2-25.8) in arm A versus 3.5 (2.3-6.1) and 10.6 (8.5-20.8) in arm B [HR = 1.19 (0.82-1.72) and HR = 0.97 (0.58-1.61)], respectively. Grade ≥3 treatment-related adverse events had higher incidence in arm B versus A (47.6% vs 16.3%), and quality of life was significantly worse in arm B. Patients with positive MGMT expression by IHC did not benefit from CAPTEM.Temozolomide-based therapy warrants further investigation in molecularly hyperselected subgroups.
SCIDOT-28. TARGETED NANOPARTICLES FOR IMPROVED DRUG DELIVERY TO MEDULLOBLASTOMA
Authors: Joelle P Straehla, Natalie Boehnke, Tamara G Dacoba, Paula T Hammond
Journal: Neuro-Oncology (2019)

Abstract Platinum-based agents remain a key component of therapy for children with medulloblastoma, despite significant systemic side effects and only modest blood-brain barrier (BBB) penetration. Cisplatin has a cerebrospinal fluid-to-plasma ratio &lt;5% and dose-limiting side effects of nephrotoxicity, ototoxicity, and myelosuppression. Improving delivery of cisplatin across the BBB and selectively accumulating in tumors could improve its therapeutic index. To this end, we are leveraging chemical engineering techniques to rationally design cisplatin nanoparticles (NPs) to cross the BBB and preferentially enter medulloblastoma tumor cells. Using the layer-by-layer (LbL) platform to ‘wrap’ polyelectrolytes around a NP core by iterative electrostatic adsorption, we screened six negatively charged polypeptide and polysaccharide outer layers in medulloblastoma cell lines. Poly-L-aspartic acid (PLD) layered NPs had significant accumulation in tumor cells after 24 hours incubation, with an uptake index of 18±4 over unlayered control NPs. Next, we generated propargyl-functionalized PLD and used click chemistry to covalently conjugate the BBB shuttle ligands glutathione, angiopep-2, and transferrin, which have been shown to mediate transcytosis across brain endothelial cells. PLD layered NPs functionalized with angiopep-2 and transferrin had enhanced uptake in medulloblastoma tumor cells and NPs functionalized with glutathione were non-inferior to PLD layered NPs. After incubation with endothelial cells in vitro, all three BBB shuttle ligands enhanced uptake of PLD layered NPs over unlayered and non-functionalized control NPs. We then incorporated cisplatin into the nanoparticle core of this platform. Cisplatin-loaded NPs with PLD layering and ligand functionalization were more effective than free cisplatin as measured by IC50 over 72 hours in culture, and led to faster apoptosis as assessed by flow cytometry with annexin V and propidium iodide staining. In summary, functionalized nanoparticles are a promising platform to modulate drug delivery to medulloblastoma. In vivo studies using an orthotopic xenograft model are underway to investigate biodistribution, efficacy, and toxicity.
NIMG-56. A MULTIMODAL 7 TELSA MRI INVESTIGATION OF LONG-TERM EFFECTS OF RADIOTHERAPY ON THE ADOLESCENT BRAIN &amp; COGNITION
Authors: Melanie Morrison, Sivakami Avadiappan, Justin Yuan, Schuyler Stoller, Angela Jakary, Sabine Mueller, Annette Molinaro, Anu Banerjee, Christopher Hess, Steve Braunstein, Janine Lupo
Journal: Neuro-Oncology (2019)

Abstract INTRODUCTION Radiation therapy (RT) remains an integral role in the treatment of adolescent brain tumors, despite evidence of its long-term effects including cognitive impairment, vascular injury and reduced white matter integrity. While prior studies have related vascular injury to cognitive decline and associated more severe cognitive impairment with a whole-brain versus a focal RT approach, the relationship between underlying imaging, clinical, and treatment parameters has yet to be explored in this population. In this study we used multimodal 7 Tesla MR imaging to probe RT-induced changes in the brain and identified risk factors for clinical outcome. METHODS Twenty-three patients (age 6–25 years) with non-supratentorial tumors treated with RT as children and 4 nonirradiated control patients (ages 13–16 years) were scanned on a 7T MRI system; eight patients underwent serial imaging 0.9–3.7 years following the first scan. Simultaneous MR-veniography and angiography, and 90-direction, dual-shell multi-band diffusion MRI were used to assess the relationships among cerebral microbleed (CMB) development, changes in arterial radii, and whole-brain white matter connectivity. A computerized cognitive battery (Cogstate) evaluated multiple domains of cognitive function. Multiple univariate and multivariate regression models with multiple comparison corrections identified risk factors. RESULTS Cognitive status measured via executive function and working memory tasks revealed the strongest associations with type of RT and imaging parameters. Specific risk factors for worse outcome included whole-brain RT, RT at a younger age, and time since RT. On imaging this corresponded to increased CMB burden, decreased arterial volume, and reduced global structural connectivity; intrasubject serial imaging followed these trends. CONCLUSION 7T-MRI was highly sensitive to CMBs with cumulative incidence rates greatly exceeding prior 3T studies in this population. This work demonstrates the value of multimodal 7T-MRI in providing metrics that reflect cognitive deficits arising from RT and identifying patients who would benefit the most from cognitive rehabilitation.
Real-World (RW) Treatment Patterns and Patient-Related Factors Including Quality of Life (QoL), Medication Adherence, and Actigraphy in Community Patients (pts) with Newly Diagnosed Multiple Myeloma (NDMM) Transitioning from Bortezomib (btz) to Ixazomib: The US MM-6 Community-Based Study
Authors: Stephen J Noga, Robert M. Rifkin, Sudhir Manda, Ruemu Ejedafeta Birhiray, Roger M. Lyons, Presley Whidden, Robert L. Schlossman, Bingxia Wang, Ralph V. Boccia
Journal: Blood (2019)
Shortage of Nurses
Authors: B. H. Kirman
Journal: BMJ (1947)

<h3>ABSTRACT</h3> Retrograde monosynaptic tracing using glycoprotein-deleted rabies virus is an important component of the toolkit for investigation of neural circuit structure and connectivity. It allows for the identification of first-order presynaptic connections to cell populations of interest across both the central and peripheral nervous system, helping to decipher the complex connectivity patterns of neural networks that give rise to brain function. Despite its utility, the efficiency with which genetically modified rabies virus spreads retrogradely across synapses remains uncertain. While past studies have revealed conditions that can increase or decrease the numbers of presynaptic cells labeled, it is unknown what proportion of total inputs to a starter cell of interest are labeled. It is also unknown whether synapses that are more proximal or distal to the cell body are labeled with different efficiencies. Here we use a new rabies virus construct that allows for the simultaneous labeling of pre and postsynaptic specializations to quantify efficiency of spread at the synaptic level in mouse primary visual cortex. We demonstrate that with typical conditions about 40% of first-order presynaptic excitatory inputs are labeled. We show that using matched tracing conditions there is similar efficiency of spread from excitatory or inhibitory starter cell types. Furthermore, we find no difference in the efficiency of labeling of excitatory inputs to postsynaptic sites at different subcellular locations.
Optimization of osmotic blood-brain barrier opening to enable intravital microscopy studies on drug delivery in mouse cortex
Authors: Chengyan Chu, Anna Jablonska, Wojciech G. Lesniak, Aline M. Thomas, Xiaoyan Lan, Raleigh M. Linville, Shen Li, Peter C. Searson, Guanshu Liu, Monica Pearl, Martin G. Pomper, Miroslaw Janowski, Tim Magnus, Piotr Walczak
Journal: Journal of Controlled Release (2019)
Short-Term Risk of Progression of Patients with Asymptomatic Monoclonal Gammopathies to Active Multiple Myeloma: The Critical Impact of the Tumoral Mass
Authors: Anna Benedetta Dalla Palma, Laura Notarfranchi, Jessica Crosara, Mario Pedrazzoni, Fabrizio Accardi, Valentina Marchica, Denise Toscani, Emanuela Vicario, Paola Storti, Nicola Giuliani
Journal: Blood (2019)
Chromatin Structure Dynamics Preserve Genome Stability in Multiple Myeloma
Authors: Antonis Kokkalis, Praveen Anand, Monica S. Nair, Johannes M. Waldschmidt, Julia Frede, Tushara Vijaykumar, Amy Guillaumet-Adkins, Valeriya Dimitrova, Birgit Knoechel, Jens G. Lohr
Journal: Blood (2019)